Insulin pen supplier Companion Medical reported on Thursday the receipt of approval from the US Food and Drug Administration (FDA) for the use of its InPen diabetes management system with Novo Nordisk's Fiasp rapid-acting insulin.

This FDA marketing clearance for the company's InPen with Fiasp insulin adds to its existing solutions for managing insulin-dependent diabetes, which to date have supported Humalog and Novolog.

According to the company, Fiasp is indicated for dosing at mealtime, or within 20 minutes after starting a meal, and is recommended for patients who need dose timing flexibility or who tend to dose late.

The InPen system includes a smart insulin pen connected to an integrated diabetes management app to help users calculate insulin doses, receive missed dose reminders, track active insulin and send reports from their phones directly to their caregivers.

The 'Insights by InPen' report aggregates glucose, insulin and meal data into detailed reports with daily views which enables providers to monitor glucose control and adherence patterns, identify the cause and effect of diabetes decisions and help make more informed targeted improvements to therapy. InPen is available in the US by prescription only.